CN107206067A - 使用抗‑ang2抗体的方法 - Google Patents

使用抗‑ang2抗体的方法 Download PDF

Info

Publication number
CN107206067A
CN107206067A CN201580035986.9A CN201580035986A CN107206067A CN 107206067 A CN107206067 A CN 107206067A CN 201580035986 A CN201580035986 A CN 201580035986A CN 107206067 A CN107206067 A CN 107206067A
Authority
CN
China
Prior art keywords
cancer
antibody
ang2
dose
functional portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580035986.9A
Other languages
English (en)
Chinese (zh)
Inventor
D.赖
R.西科斯基
D.海曼
N.A.里斯维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN107206067A publication Critical patent/CN107206067A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580035986.9A 2014-05-07 2015-05-06 使用抗‑ang2抗体的方法 Pending CN107206067A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461989884P 2014-05-07 2014-05-07
US61/989884 2014-05-07
US201462005525P 2014-05-30 2014-05-30
US62/005525 2014-05-30
PCT/US2015/029447 WO2015171747A1 (en) 2014-05-07 2015-05-06 Methods of using anti-ang2 antibodies

Publications (1)

Publication Number Publication Date
CN107206067A true CN107206067A (zh) 2017-09-26

Family

ID=54392949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580035986.9A Pending CN107206067A (zh) 2014-05-07 2015-05-06 使用抗‑ang2抗体的方法

Country Status (12)

Country Link
US (1) US20170058025A1 (https=)
EP (1) EP3139956A4 (https=)
JP (1) JP2017514854A (https=)
KR (1) KR20170003651A (https=)
CN (1) CN107206067A (https=)
AU (1) AU2015256052A1 (https=)
CA (1) CA2946906A1 (https=)
HK (1) HK1244445A1 (https=)
IL (1) IL248391A0 (https=)
RU (1) RU2016147521A (https=)
SG (1) SG11201609168PA (https=)
WO (1) WO2015171747A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US10836819B2 (en) 2016-08-23 2020-11-17 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
JP2020522479A (ja) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 個別化された癌ワクチンを作製する方法
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
EP3950725A4 (en) 2019-05-08 2023-07-19 Daikin Industries, Ltd. Fluoropolymer production method and fluoropolymer
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097325A1 (en) * 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
WO2011106300A2 (en) * 2010-02-23 2011-09-01 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
CN102250247A (zh) * 2011-06-15 2011-11-23 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
CN102549015A (zh) * 2009-07-29 2012-07-04 瑞泽恩制药公司 针对人血管生成素-2的高亲和力人抗体
US20130129722A1 (en) * 2009-07-29 2013-05-23 Regeneron Pharmaceuticals, Inc. Methods for Treating Cancer by Administering an Anti-Ang-2 Antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101607038B1 (ko) * 2011-11-21 2016-04-11 모토로라 모빌리티 엘엘씨 시간 예측을 위한 병치된 픽처의 암시적 결정 및 결합된 암시적 및 명시적 결정
KR20150038593A (ko) * 2012-08-07 2015-04-08 제넨테크, 인크. 교모세포종의 치료를 위한 조합 요법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097325A1 (en) * 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
CN102549015A (zh) * 2009-07-29 2012-07-04 瑞泽恩制药公司 针对人血管生成素-2的高亲和力人抗体
US20130129722A1 (en) * 2009-07-29 2013-05-23 Regeneron Pharmaceuticals, Inc. Methods for Treating Cancer by Administering an Anti-Ang-2 Antibody
WO2011106300A2 (en) * 2010-02-23 2011-09-01 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
CN103237810A (zh) * 2010-02-23 2013-08-07 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
CN102250247A (zh) * 2011-06-15 2011-11-23 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEFFREY L. BROWN ET AL.: "A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models", 《MOL CANCER THER》 *
张中林: "人促血管生成素2单链抗体对裸鼠人肝癌血管生成及肿瘤生长的作用", 《中华试验外科杂志》 *

Also Published As

Publication number Publication date
HK1244445A1 (zh) 2018-08-10
KR20170003651A (ko) 2017-01-09
SG11201609168PA (en) 2016-12-29
JP2017514854A (ja) 2017-06-08
RU2016147521A (ru) 2018-06-09
AU2015256052A1 (en) 2016-11-10
EP3139956A4 (en) 2017-11-29
CA2946906A1 (en) 2015-11-12
WO2015171747A1 (en) 2015-11-12
RU2016147521A3 (https=) 2018-12-27
EP3139956A1 (en) 2017-03-15
US20170058025A1 (en) 2017-03-02
IL248391A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CN107206067A (zh) 使用抗‑ang2抗体的方法
Rudin et al. SKYSCRAPER-02: primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab+ carboplatin+ etoposide with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer
Shimamoto et al. Peptibodies: A flexible alternative format to antibodies
Chappelow et al. Neovascular age-related macular degeneration: potential therapies
US20250032583A1 (en) IL-10 Monomer Fusion Protein and Use thereof
CN109715805A (zh) 核酸-多肽组合物及其用途
KR20170136542A (ko) C/EBP 알파 saRNA 조성물 및 사용 방법
Krug et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma
CN102481365A (zh) 用dll4拮抗剂和化疗剂治疗癌症的方法
JP2017043620A (ja) 溶解性ペプチド−Ｈｅｒ２／ｎｅｕ（ヒト上皮成長因子レセプター２）リガンド結合体およびその使用方法
WO2022218292A1 (zh) 白介素2突变体及其应用
Lee et al. Options for second-line treatment in metastatic colorectal cancer
Duan et al. Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced NSCLC harboring EGFR exon 20 insertion mutations: a phase 1 trial
CN104415335A (zh) 体内个体化系统免疫治疗方法和装置
AU2024299158A1 (en) Method for treatment of tumor by using recombinant oncolytic virus in combination with small-molecule anticancer drug
KR20240149421A (ko) 암 면역요법을 위한 조성물 및 방법
WO2026001832A1 (zh) 核酸在制备防治恶液质的药物中的应用和施用方法
CN116802303A (zh) 用于预防和治疗癌症的沙门氏菌菌株及其用途
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
US20230212247A1 (en) Modified cxcl10 for immunotherapy of cancer diseases
CN120344265A (zh) 单独使用双特异性EGFR x CD28抗体或其与抗PD-1抗体组合使用治疗癌症的方法
CN106699885B (zh) 一种人源抗vegfr2抗体及其应用
CN116535491B (zh) 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
KR20260008678A (ko) 아포지질단백질 및 Fc 부위 결합 펩타이드를 포함하는 융합 단백질 및 이의 용도
WO2026060032A2 (en) Nucleic acids encoding engineered chimeric fusion proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244445

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1244445

Country of ref document: HK